Drug intelligence / Profile preview

cixutumumab + temsirolimus

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of cixutumumab, a fully human immunoglobulin G1 monoclonal antibody directed against the type 1 insulin-like growth factor receptor (IGF-1R), and temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor. This combination was developed based on the rationale that mTOR inhibitors mediate AKT activation through an IGF-1R-dependent mechanism, and combining these agents could enhance anticancer activity by modulating resistance to mTOR inhibition.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on cixutumumab + temsirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cixutumumab + temsirolimus.

Explore the full profile